Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 May 13:13:1633-1641.
doi: 10.2147/DDDT.S186992. eCollection 2019.

Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials

Xiangrong Shu  1 , Liqun Chi  2
Affiliations
Meta-Analysis

Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials

Xiangrong Shu et al. Drug Des Devel Ther. .

Abstract

Objective: Pravastatin has been suggested to increase circulating adiponectin in humans. However, results of randomized controlled trials (RCTs) are inconsistent. We aimed to systematically evaluate the influence of pravastatin on circulating adiponectin in humans by performing a meta-analysis of RCTs.

Materials and methods: Studies were identified via systematic searching of PubMed, Embase, and Cochrane's Library databases. A random effect model was used to pool the results. Meta-regression and subgroup analyses were applied to explore the source of heterogeneity.

Results: Eight RCTs with nine comparisons of 595 participants were included. Pravastatin treatment was associated with a significant increased level of circulating adiponectin as compared with controls (weighted mean difference [WMD] =0.63 µg/mL; 95% CI, 0.17-1.09 µg/mL; P=0.007) with moderate heterogeneity (I2=28%). These results were confirmed by meta-analysis of double-blinded placebo-controlled RCTs (WMD =0.82 µg/mL; P=0.01). Meta-regression analyses indicated that proportions of males in each study were positively correlated with the effect of pravastatin on adiponectin (coefficient: 0.015, P=0.03). Subgroup analyses confirmed that pravastatin significantly increased adiponectin in studies of males (WMD =1.41 µg/mL; P=0.008), but not in those of females (WMD =-0.04 µg/mL; P=0.94).

Conclusion: Pravastatin treatment is associated with increased circulating adiponectin. Gender difference may exist regarding the effect of pravastatin treatment on adiponectin.

Keywords: adiponectin; meta-analysis; pravastatin; randomized controlled trials.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of database searching and study selection.
Figure 2
Figure 2
Forest plot for the meta-analysis of effect of pravastatin treatment on circulating adiponectin as compared with controls. Notes: (A) Forest plot for the overall meta-analysis; (B) forest plot for the meta-analysis with double-blinded, placebo-controlled randomized controlled trials.
Figure 3
Figure 3
Correlation between proportions of male participants in each study and the effect of pravastatin treatment on circulating adiponectin: result of meta-regression analysis. Abbreviation: WMD, weighted mean difference.
Figure 4
Figure 4
Forest plot for the meta-analysis of effect of pravastatin treatment on circulating adiponectin stratified by genders of the participants.
Figure 5
Figure 5
Funnel plot for the meta-analysis of effect of pravastatin treatment on circulating adiponectin. Abbreviations: SE, standard error; WMD, weighted mean difference.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Peters B, Maitland-van der Zee AH. Pharmacogenomic importance of pravastatin. Pharmacogenomics. 2008;9(9):1207–1210. - PubMed
    1. Gotto AM. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol. 2005;96(5A):34–38. - PubMed
    1. del Sol AI, Nanayakkara PW. Pravastatin: an evidence-based statin? Expert Opin Drug Metab Toxicol. 2008;4(6):821–825. - PubMed
    1. McGovern ME, Mellies MJ. Long-term experience with pravastatin in clinical research trials. Clin Ther. 1993;15(1):57–64. - PubMed
    1. Byington RP, Sacks FM. Lessons learned from the prospective pravastatin Pooling Project. Curr Atheroscler Rep. 2004;6(5):366–374. - PubMed

MeSH terms